STOCK TITAN
  1. Home
  2. News
  3. MRNA

Moderna Inc - MRNA STOCK NEWS

Welcome to our dedicated news page for Moderna (Ticker: MRNA), a resource for investors and traders seeking the latest updates and insights on Moderna.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Moderna's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Moderna's position in the market.

News
Moderna Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Provides Business Updates
Rhea-AI Summary
Moderna, Inc. (MRNA) reported fourth quarter revenues of $2.8 billion, with a net income of $217 million and diluted EPS of $0.55. Full-year revenues were $6.8 billion, with a net loss of $(4.7) billion and diluted EPS of $(12.33). The company reaffirmed 2024 expected product sales of $4 billion and expects regulatory approvals for its investigational RSV vaccine in the first half of 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
13.53%
Tags
earnings
-
News
Moderna Chief Executive Officer Stéphane Bancel Elected to National Academy of Engineering
Rhea-AI Summary
Moderna, Inc. announced that CEO Stéphane Bancel has been elected to the National Academy of Engineering for his contributions to engineering and the development and manufacturing of pharmaceutical products, including the COVID-19 vaccine. Bancel has been with Moderna for 13 years, leading the company from startup to global commercial enterprise. The company has 45 mRNA therapeutic and vaccine programs in its pipeline, with nine in late-stage development. Bancel's previous experience includes roles at bioMérieux SA and Eli Lilly and Company. Moderna's co-founder and Chairman, Noubar Afeyan, was also elected to the Academy in 2022. The NAE's mission is to advance the welfare and prosperity of the nation by providing independent advice on matters involving engineering and technology.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.73%
Tags
none
-
News
Moderna to Report Fourth Quarter and Full Year 2023 Financial Results on Thursday, February 22, 2024
Rhea-AI Summary
Moderna, Inc. (MRNA) will host a live conference call and webcast to report its fourth quarter and full year 2023 financial results and provide a corporate update on February 22, 2024. The webcast will be available on the Moderna website under 'Events and Presentations' and will be archived for one year after the call.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.01%
Tags
conferences earnings
News
Moderna Named to Fortune's List of World's Most Admired Companies
Rhea-AI Summary
Moderna, Inc. (MRNA) has been recognized on Fortune's World's Most Admired Companies list as part of its 'All-Star' top-50 companies. This marks the first year on the list for Moderna, reflecting its transformative platform technology. The company is committed to expanding the field of mRNA medicine with 45 therapeutic and vaccine programs, nine of which are in late-stage development. Moderna's focus on public health, access, and equality has earned it recognition for investment in people and innovation. The recognition is based on a survey of more than 3,700 executives, directors, and analysts, who ranked enterprises on nine criteria related to financial performance and corporate reputation.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.01%
Tags
none
-
News
Moderna Provides Business and Pipeline Updates at 42nd Annual J.P. Morgan Healthcare Conference
Rhea-AI Summary
Moderna, Inc. (MRNA) announces impressive 2023 product sales of $6.7 billion, with an increased U.S. COVID-19 market share to 48%. The company expects $4 billion in product sales in 2024, plans to return to sales growth in 2025, and break even in 2026. Moderna highlights nine late-stage programs with anticipated milestones in 2024 and 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.89%
Tags
none
-
News
Moderna to Present at the 42nd Annual J.P. Morgan Healthcare Conference
Rhea-AI Summary
Moderna, Inc. (Nasdaq:MRNA) CFO to Present at J.P. Morgan Healthcare Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.77%
Tags
conferences
News
Moderna Announces New England Journal of Medicine Publication of Pivotal Phase 3 Clinical Safety and Efficacy Data For MRNA-1345, The Company’s Investigational Respiratory Syncytial Virus (RSV) Vaccine
Rhea-AI Summary
Moderna, Inc. (Nasdaq:MRNA) has submitted marketing authorizations globally for mRNA-1345, its vaccine candidate for respiratory syncytial virus (RSV), and continues to prepare for an expected 2024 marketing launch. The positive Phase 3 clinical study results evaluating mRNA-1345 were published in The New England Journal of Medicine, demonstrating safety and efficacy data from the ConquerRSV trial. Moderna is the only company to have developed an mRNA-based RSV vaccine, with potential best-in-class profile and the only ready-to-use RSV vaccine available in single-dose prefilled syringes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.16%
Tags
clinical trial
-
News
First In Vivo CAR-M Lead Candidate Nominated Under Carisma-Moderna Collaboration
Rhea-AI Summary
Carisma Therapeutics Inc. (Nasdaq: CARM) has announced the nomination of its first lead candidate under the collaboration with Moderna, Inc. (Nasdaq: MRNA) to target an antigen present on a solid tumor with significant unmet medical need. This strategic collaboration brings together Carisma's CAR-M platform with Moderna's mRNA and LNP technologies to develop in vivo CAR-M therapeutics for oncology.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.81%
Tags
none
-
News
Moderna And Merck Announce mRNA-4157 (V940) In Combination with Keytruda(R) (Pembrolizumab) Demonstrated Continued Improvement in Recurrence-Free Survival and Distant Metastasis-Free Survival in Patients with High-Risk Stage III/IV Melanoma Following Complete Resection Versus Keytruda at Three Years
Rhea-AI Summary
Moderna, Inc. (MRNA) and Merck (MRK) announced follow-up data from the Phase 2b randomized KEYNOTE-942/mRNA-4157-P201 study, showing that mRNA-4157 in combination with KEYTRUDA reduced the risk of recurrence or death by 49% and the risk of distant metastasis or death by 62% compared to KEYTRUDA alone in stage III/IV melanoma patients with high risk of recurrence following complete resection. The companies have initiated Phase 3 studies in the adjuvant setting in patients with high-risk melanoma and non-small cell lung cancer and plan to rapidly expand to additional tumor types.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.15%
Tags
none
News
Moderna Announces Changes to Commercial Organization to Prepare for Multiple Product Launches in 2024 and 2025
Rhea-AI Summary
Moderna, Inc. (NASDAQ:MRNA) announced changes to its operating model to focus on driving sales of its COVID-19 vaccine and preparing for the launch of its RSV vaccine in 2024. The company plans to increase executive focus on driving sales of Spikevax and the expected launch of its RSV vaccine next year. Stephane Bancel, CEO of Moderna, will assume responsibility for sales and marketing in 2024, while Stephen Hoge, M.D., President of Moderna, will take on pipeline commercial strategy and Medical Affairs. Arpa Garay, previously Chief Commercial Officer, is expected to leave the Company in the coming months.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.83%
Tags
none
Stock MRNA logo
Moderna Inc

Nasdaq:MRNA

MRNA Rankings

#301 Ranked by Market Cap
#4725 Ranked by Stock Gains
N/A Ranked by Dividends

MRNA Stock Data

40.26B
344.86M
9.63%
73.16%
5.6%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
US
Cambridge

About MRNA

moderna is pioneering messenger rna therapeutics™, an entirely new in vivo drug modality that produces human proteins or antibodies inside patient cells, which are in turn active intracellularly or secreted. this breakthrough platform addresses currently undruggable targets, and offers a superior alternative to existing drug modalities for a wide range of disease conditions. moderna has developed a broad intellectual property estate including more than 200 patent applications with more than 10,000 claims ranging from novel nucleotide chemistries to specific drug compositions. the company plans to develop and commercialize its innovative mrna drugs—initially for rare diseases and oncology—while partnering drug candidates in other therapeutics areas in order to rapidly deliver this innovation to patients. based in cambridge, massachusetts, moderna is privately held and was founded in 2010 by flagship venturelabs in association with leading scientists from boston children’s hospital a